AAP
VOR icon

Arax Advisory Partners’s Vor Biopharma VOR Stock Holding History

Arax Advisory Partners’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-26
Closed -$370 – 2762
2024
Q3 		$370 Hold
26
– – ﹤0.01% 2442
2024
Q2 		$528 Buy
+26
New +$841 ﹤0.01% 2322

Other funds holding VOR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arax Advisory Partners's VOR Position: Q4 2024 in Review

Arax Advisory Partners sold out of Vor Biopharma (VOR) in Q4 2024, closing a stake of 26 shares — an estimated $370 sold.

Arax Advisory Partners first reported a position in VOR in Q2 2024 and held it in 2 quarters. The position peaked at $528 in Q2 2024. 50 funds tracked by Wall St. Rank hold VOR as of Q4 2024.

  • Arax Advisory Partners reported no remaining Vor Biopharma position as of Q4 2024 after selling out during the quarter.
  • Arax Advisory Partners sold 26 Vor Biopharma shares in Q4 2024, an estimated $370.
  • Arax Advisory Partners first reported a position in Vor Biopharma in Q2 2024 and held it in 2 quarters.
  • Arax Advisory Partners's Vor Biopharma position peaked at $528 in Q2 2024.
  • 50 funds tracked by Wall St. Rank held Vor Biopharma as of Q4 2024.

Based on Arax Advisory Partners's 13F filing for Q4 2024, filed 5 Feb 2025.